On paper, FinalDose sounds like the kind of pitch that venture capitalists might dismiss before the second slide. A London biotech with five employees as of mid-2026 claims to have cracked a problem that has vexed the pharmaceutical industry for decades: how to drug the roughly 80% of cancer-driving proteins that lack the molecular pockets needed for conventional therapies to latch onto. The solution, according to the company? Forget the proteins entirely. Go straight for the DNA.
What makes the claim more than cocktail-party chatter is the pedigree behind it—three Oxford PhDs, a Y Combinator stamp, and a scientific premise that sits squarely at the intersection of several experimental but increasingly credible approaches in precision medicine. What's missing, however, is harder to overlook: as of mid-2026, there is no public record of peer-reviewed data, patents, disclosed funding figures, or really any evidence beyond a company page and a compelling narrative.
FinalDose emerged from stealth in May 2026 and describes its platform as a "programmable drug"—a DNA-sensing molecule engineered to scan the genome for specific cancer-driving sequences, then activate a kill switch to destroy diseased cells. Swap out the targeting sequence, the founders say, and you've got a new drug for a different cancer mutation. It's a proposition elegant enough to turn heads, particularly among investors fatigued by incremental progress in oncology. Whether it's chemistry that works in human bodies is another question entirely.
The Undruggable Genome (and Why It Might Not Stay That Way)
The "80% undruggable" figure has become something of a rallying cry in drug development, though the number itself is contested and represents an estimate rather than a precise count. Multiple reviews published over the past couple of years estimate that the majority of disease-relevant proteins lack the binding pockets that small-molecule drugs require—especially intrinsically disordered proteins and the interaction surfaces where proteins meet. Global initiatives like Target 2035 exist for precisely this reason: to expand the chemical toolkit across the genome and chip away at what can't yet be reached.
But the definition of "undruggable" has been shifting faster than usual lately. Molecular glues and targeted protein degradation technologies have cracked targets once thought inaccessible. In April, Astellas began dosing patients in a Phase 3 trial of setidegrasib, a degrader targeting the KRAS G12D mutation—a genetic alteration that, until quite recently, sat firmly in the undruggable column. A survey published in Communications Chemistry earlier in the year counted at least nine other KRAS G12D small-molecule programs in clinical development.
The progress is real. It's also painstaking. Each new druggable target represents years of structural biology, medicinal chemistry, and failed compounds. FinalDose's pitch—if the science holds—would bypass that grind by targeting the mutation at the level of DNA, not the misshapen protein it produces.
A Search-and-Destroy Molecule
According to the company's Y Combinator profile, FinalDose's platform centers on a molecule designed to hunt for hardcoded DNA sequences inside cancer cells. Once it binds to the target sequence, the molecule undergoes a conformational shift that activates a cytotoxic payload—think of it as a warhead with an address label. The founders claim the core structure can be "reprogrammed" simply by changing the guide sequence, which in theory could collapse R&D timelines for new indications.
The team is lean but experienced. CEO Jeff Liu holds an Oxford DPhil in oncology and previously led Vivid Dx, a diagnostics startup that reportedly raised $15 million and developed what it claimed was the world's fastest sepsis diagnostic. Chief Scientific Officer Li-Yao Huang spent five years as a postdoc at Oxford's MRC Weatherall Institute, running CRISPR screens to identify druggable targets in BRCA1-deficient cancers and resistance mechanisms to PARP inhibitors. Chief Technology Officer Steven Lin, also an Oxford PhD, has a background in computational biology and contributed to UK Biobank genetics analyses during the pandemic.
What the company does not have—at least not in the public domain as of mid-2026—is proof. No disclosed preclinical efficacy data. No pharmacokinetic profiles. No demonstration that the molecule can actually reach tumor DNA in meaningful concentrations, or that it won't bind off-target sites elsewhere in the genome and wreak havoc in healthy tissue.
Old Ideas, New Wrappers
The notion of targeting DNA sequences directly isn't novel, though clinical success has been elusive. More than a decade ago, researchers published work on KR12, a polyamide molecule conjugated to an alkylating agent, designed to recognize and bind KRAS G12D and G12V mutations at the DNA level. In xenograft models, it downregulated mutant KRAS and suppressed tumor growth. But a review from a few years back noted that these polyamide compounds suffer from off-target genomic binding and delivery challenges—problems that have kept them confined to academic labs ever since.
Peptide nucleic acids (PNAs) represent another approach. Studies through 2025 have shown that cell-penetrating peptide-PNA conjugates could selectively repress KRAS G12D expression both in vitro and in vivo. Delivery to the nucleus in solid tumors, however, remains a stubborn barrier. DNA nanorobots and aptamer-gated origami structures—molecular machines that can sense biomarkers and release payloads conditionally—have demonstrated proof-of-concept. Translating them into systemically deliverable drugs has proven slow work.
What FinalDose is proposing isn't exactly unprecedented, in other words. But if the company has solved the delivery and specificity problems that have stymied predecessors, it would represent a genuine breakthrough.
The Programmable Therapeutics Rush
FinalDose is entering a market already crowded with startups betting on programmable biology, though most are working at the RNA or protein level rather than DNA.
Strand Therapeutics, which raised $153 million in Series B funding announced in August 2025, is advancing programmable mRNA circuits—tumor-restricted cytokines that activate only in malignant tissue. The company presented early Phase 1 data for its lead candidate at ASCO and announced plans to present in vivo CAR-T data at the American Society of Gene & Cell Therapy meeting.
Omega Therapeutics took a different route with an mRNA-encoded epigenomic controller that targets regulatory DNA upstream of the MYC oncogene. The company reported proof-of-mechanism signals from a Phase 1 trial in hepatocellular carcinoma a couple of years back, though it has since shifted strategic focus and is exploring partnerships—a polite way of saying the initial plan didn't pan out as hoped.
Senti Biosciences is building logic-gated cell therapies—NK and CAR constructs with multi-input circuits that sense the tumor microenvironment. Earlier this year, Senti disclosed it had received Regenerative Medicine Advanced Therapy (RMAT) designation for one of its programs, though the company also flagged cash constraints in the same breath.
These programs share a common thread: they're trying to embed decision-making logic directly into therapies. But they're doing it with mRNA or engineered cells, not small molecules or DNA-binding constructs. FinalDose's approach—if the chemistry works—could offer simplicity and programmability in a single dose. That's the pitch, anyway.
Three Hurdles (At Least)
Any DNA-targeting therapeutic faces a trio of existential challenges.
First, delivery. Getting a molecule into the nucleus of solid tumor cells in sufficient concentration—without being cleared systemically or trapped in endosomes—has stymied nucleic acid therapies for years. RNA therapeutics have made progress with lipid nanoparticles, but DNA-targeting adds the further challenge of nuclear localization. No small feat.
Second, specificity. The genome is vast. Chromatin accessibility varies by cell state. Even high-affinity DNA binders can tolerate mismatches, which means a molecule designed to recognize a cancer mutation might also bind off-target sites across the genome. If that happens, the kill switch activates in healthy cells—a recipe for systemic toxicity. The polyamide review mentioned earlier explicitly warned of genome-wide binding issues.
Third, regulation. If FinalDose's molecule incorporates genome-editing components or acts on DNA in ways that resemble gene therapy, it may fall under the FDA's Center for Biologics Evaluation and Research (CBER) rather than the small-molecule-focused Center for Drug Evaluation and Research (CDER). The FDA has published guidance on human gene therapy products incorporating genome editing, and more recently released draft guidance on using next-generation sequencing to assess off-target effects and chromosomal integrity. Any therapy that touches the genome will face heightened analytical scrutiny—perhaps more than the founders initially expected.
For oncology specifically, the FDA's Project Optimus now requires rigorous dose optimization before approval. A cytotoxic DNA-targeting agent would need to demonstrate a therapeutic window, and that window might be narrow indeed.
Market Winds (Blowing in the Right Direction)
The broader oncology market, at least, offers strong tailwinds. According to industry analyses from April 2026, global oncology medicine spending has been climbing steadily and is projected to exceed $400 billion by 2028, with the U.S. accounting for roughly half. Precision therapies, antibody-drug conjugates, radioligand therapies, and CAR-T expansions are driving growth.
Within that landscape, RNA therapeutics are gaining momentum. Recent analyses note approximately 25 FDA-approved RNA drugs to date and substantial deal value in the space over the past year. The Oligonucleotide Therapeutics Society has cataloged multiple RNA approvals recently, including treatments for rare metabolic disorders.
Industry analysts estimate the oligonucleotide therapeutics market at somewhere in the high single-digit billions, with strong growth projected through the early part of the next decade—though these estimates vary widely depending on who's counting and what they're including. What's clear is that investors and pharma acquirers are paying attention to modalities beyond traditional small molecules.
What Comes Next (and What Doesn't)
FinalDose will need to show data, and soon. The company's YC launch page is sparse, and there's no public disclosure of preclinical results, let alone clinical plans. The founders' credentials are strong—Oxford PhDs, postdoctoral work at leading institutes, prior startup experience—but credentials don't substitute for efficacy and safety profiles. The biotech graveyard is littered with brilliant scientists whose chemistry didn't survive contact with biology.
The company will also need to demonstrate that its "programmable" claim holds up under scrutiny. Swapping a guide sequence sounds elegant in a pitch deck, but regulatory agencies will want to see that each new variant behaves predictably, that off-target profiles don't shift unexpectedly, and that manufacturing can be scaled without loss of quality. These are not trivial problems.
In the near term, watch for patent filings, partnership announcements, or preclinical publications. FinalDose's competitors in programmable therapeutics—Strand, Omega, Senti—are all presenting updated data at major scientific meetings this year and next. If FinalDose can deliver even preliminary in vivo proof-of-concept for sequence-specific cell killing with an acceptable safety margin, it would validate the approach and attract the kind of Series A capital that could fund IND-enabling studies.
The "undruggable" genome isn't going to stay undruggable forever. KRAS G12D inhibitors and degraders are proof enough of that. But whether the solution involves DNA-targeting molecules that rewire themselves for each new indication—or whether delivery and specificity challenges will keep this approach confined to academic conferences—remains an open question.
FinalDose is betting on the former. The rest of the biotech industry will be watching to see if the chemistry, and the company, can deliver.
